

April 22, 2024
Web Announcement 3337

Wegovy (semaglutide) Coverage Updates Based on New FDA-Labeled Indication

On March 8, 2024, the FDA announced the approval of a new indication for use of Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in obese or overweight adults with established cardiovascular disease. Wegovy should be used in addition to a reduced calorie diet and increased physical activity.

See the [FDA announcement](#) for full recommendations.

Nevada Medicaid has updated policy to include coverage of Wegovy for this new indication in recipients who meet required prior authorization criteria in-line with FDA package labeling.